NASDAQ: MDBH We make investments that can change lives Fourth Quarter and Full Year 2024 Results March 31, 2025 FORWARD-LOOKING STATEMENTS & DISCLOSURES This presentation contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "go ...

Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was $28 million, with Big Idea investments represented by eXoZymes valued at $64 million, totaling approximately $93 million in cash and securities [58] - The stock price as of December 31 was $6.30, with approximately 9.9 million shares outstanding, resulting in a market value of $62 million, indicating a negative market value of $30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by year-end [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority for the company is to expand its investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to present one to two new Big Idea investment opportunities in the next quarter, indicating a robust pipeline of potential investments [52][53] - The company is evolving from a model of episodic deal-making to creating a consistent public venture asset class portfolio [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the increasing number of opportunities being presented, both from community members and through proactive curation [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies while managing cash expenditures, with hopes of reducing operational costs over the next 12 months [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing this opportunity, although no specific updates were provided [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier for investors to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas in 2025, with some companies already in advanced discussions for potential IPOs [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is expected to improve, facilitating new offerings, although there are uncertainties regarding FDA timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to wait for a solid footing under eXoZymes before considering any distributions to avoid disrupting the market [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]

Dallas, TX, April 01, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report on brain-computer interfaces (BCIs). Titled "Brain- Computer Interfaces (BCIs): Who's Leading, What They Own, and How IP Will Decide the Future," the report reveals how control over intellectual property—not just innovation—is shaping the future of neurotechnology. Neurological disorders represent one of the fastest-growing and highest-need ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE ANNUAL PERIOD ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41751 MDB CAPITAL HOLDINGS, LLC (Exact name of registrant as specified in its charter) Delaware 87-4366624 Securities registered pursuant to Section 12(b) of the Exchange Act: ...

Core Insights - MDB Capital Holdings, LLC is focused on launching deep technology companies and has made significant progress in a challenging venture market, highlighting the value of its public venture approach [2][6] Operational Highlights - The company successfully completed its first full year of its clearing and trading platform and has expanded its investor community by 12%, onboarding 456 new brokerage accounts and increasing assets under management from approximately $2 million to $44 million [6] - MDB Capital launched an initial public offering for eXoZymes Inc, a company spun out from UCLA, and currently owns about 47% of its outstanding shares [6] - The firm increased its analyst team to 14, screening 8,964 companies and examining 217 for potential market leadership, resulting in a strong pipeline of "Big Ideas" [6] - MDB Capital operates a self-clearing broker-dealer and an online investment platform specifically for public venture investing, enhancing its service offerings [6][8] Financial Reporting - The company filed its Form 10-K with the SEC, which includes consolidated financial results for all operations, including eXoZymes' performance until its IPO on November 14, 2024 [6]

Addison, TX, March 24, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Monday March 31, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members ...

Dallas, TX, March 05, 2025 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest PatentVest Pulse Report, "AI-Driven Data Centers – The Patent Race Reshaping AI Infrastructure." This in-depth analysis explores the rapidly evolving AI data center market, offering valuable insights into the trends, key players, and opportunities shaping the future of AI infrastructure. Enterprise data generation is projected to reach 1.2 million exaby ...

Core Insights - The continuous glucose monitoring (CGM) market is rapidly evolving, driven by technological advancements and increasing demand for diabetes management solutions [1][3][5] Market Overview - The CGM market was valued at $11.63 billion in 2024 and is projected to reach $21 billion by 2029, indicating significant growth potential [3] - An estimated 537 million adults were affected by diabetes in 2021, with projections rising to 783 million by 2045, highlighting the urgent need for effective diabetes management tools [2] Key Players and Innovations - Major companies such as Dexcom, Abbott, Medtronic, and Roche are leading the way in advancing CGM technologies and solutions [5] - Innovations include non-invasive glucose monitoring and integration with mobile applications, enhancing convenience and accuracy for users [8] Market Dynamics - The emergence of over-the-counter (OTC) CGM products is expanding access to diabetes care, particularly for non-insulin-dependent patients and wellness-focused individuals [8] - A surge in patent filings indicates a competitive landscape where companies are actively protecting their innovations [8] Intellectual Property Strategy - The CGM market is characterized by ongoing litigation trends, reflecting the high stakes involved in securing leadership positions through intellectual property [8]

Core Insights - Invizyne Technologies, Inc. has been awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF) [1][2] - The project is part of the U.S. Department of Defense's BioMADE initiative, aimed at scaling up American biomanufactured products [2][3] - The global SAF market is projected to grow at a compound annual growth rate of 52.2%, reaching $27.4 billion by 2032 [5] Project Details - The BioMADE grant will facilitate the development of an enzyme production and processing pipeline for isobutanol, which can replace conventional petroleum-based fuels [6][4] - Invizyne's technology will be deployed in 100L pilot-scale facilities as part of this initiative [6] Broader Vision and Impact - Invizyne aims to establish a framework for expanding its cell-free approach into various industrial processes beyond biofuels [8] - The company believes its biomanufacturing platform, SimplePath™, will provide significant alternatives to traditional chemical production methods [11][10] - The initiative is expected to contribute to reducing greenhouse gas emissions and fostering a shift toward renewable solutions [8][7] Industry Context - BioMADE supports the scale-up of bioindustrial manufacturing technology, enhancing American competitiveness and securing the U.S. supply chain [9] - The initiative is part of a broader effort to build a diverse and competitive workforce in the bioindustrial manufacturing ecosystem [9]

Company Overview - Invizyne Technologies, Inc. specializes in cell-free, enzyme-based biomanufacturing systems aimed at producing commercially important molecules and chemicals for everyday life [6] - The company is headquartered in Monrovia, California, and is focused on redefining biomanufacturing through its SimplePath™ platform, which transforms natural or renewable resources into valuable biochemicals [6] Initial Public Offering (IPO) Details - Invizyne Technologies announced the closing of its IPO, offering 1,875,000 shares at a public offering price of $8.00 per share, resulting in gross proceeds of approximately $15,000,000 before expenses [1][2] - The shares began trading on NASDAQ under the ticker symbol "IZTC" on November 13, 2024 [1] - The company has granted a 45-day option to the underwriter to purchase up to 281,250 additional shares to cover over-allotments [2] Concurrent Private Placement - In a concurrent private placement, Invizyne issued 93,750 warrants at a purchase price of $0.125 per warrant, each warrant allowing the purchase of one share of common stock at an exercise price of $8.00 for five years [3] Regulatory Compliance - A registration statement on Form S-1 was filed with the SEC and declared effective on November 8, 2024, allowing the public offering to proceed [4]